Aβ anti-idiotypic antibodies are present in intravenous immunoglobulin and are produced in mice following its administration

Autoimmunity

Volumn 48, Issue 4, 2015, Pages 196-200

  Loeffler, David A ^a   Klaver, Andrea C ^a   Coffey, Mary P ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Autoimmunity; Immunotherapy; IVIG; Mice

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; ANTIIDIOTYPIC ANTIBODY; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); IMMUNOGLOBULIN; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BIOTINYLATION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; ALZHEIMER DISEASE; ANIMAL; ANTIBODY SPECIFICITY; HUMAN; IMMUNOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY SPECIFICITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MICE; PEPTIDE FRAGMENTS;

EID: 84929731146     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2014.983265     Document Type: Article

References (19)

1. DoDel, R. C., Y. Du, C. Depboylu, et al. 2004. Intravenous immunoglobulins containing antibodies against beta-Amyloid for the treatment of Alzheimers disease. J. Neurol. Neurosurg. Psychiatry. 75: 1472-1474
2. Relkin, N. R., P. Szabo, B. Adamiak, et al. 2009. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging. 30: 1728-1736
3. DoDel, R., A. Rominger, P. Bartenstein, et al. 2013. Intravenous immunoglobulin for treatment of mild-to-moDerate Alzheimers disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 12: 233-243
4. Medpage Today. Alzheimers Disease: IVIG Fails in Trial (7 May 2013; accessed 20 June 2014). Available at: http://www.medpagetoday. com/Neurology/AlzheimersDisease/38939
5. DoDel, R., H. Hampel, C. Depboylu, et al. 2002. Human antibodies against amyloid beta peptiDe: a potential treatment for Alzheimers disease. Ann. Neurol. 52: 253-256
6. Smith, L. M., M. P. Coffey, A. C. Klaver, D. A. Loeffler. 2013. Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein. Int. Immunopharmacol. 16: 424-428
7. Lutz, H. U., P. Stammler, E. Jelezarova, et al. 1996. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood. 88: 184-193
8. Lutz, H. U., P. Stammler, V. Bianchi, et al. 2004. Intravenously applied IgG stimulates complement attenuation in a complementDepenDent autoimmune disease at the amplifying C3 convertase level. Blood. 103: 465-472
9. Menezes, M. C., G. Benard, M. N. Sato, et al. 1997. In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations. Int. Arch. Allergy Immunol. 114: 323-328
10. Blank, M., L. Anafi, G. Zandman-Goddard, et al. 2007. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal moDel. Int. Immunol. 19: 857-865
11. Jerne, N. K. 1974. Towards a network theory of the immune system. Ann Immunol (Paris) 125C: 373-389
12. Richter, P. H. 1975. A network theory of the immune system. Eur. J. Immunol. 5: 350-354
13. Kazatchkine, M. D., G. Dietrich, V. Hurez, et al. 1994. V regionmediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). Immunol. Rev. 139: 79-107
14. Loeffler, D. A., L. M. Smith, A. C. Klaver, et al. 2012. Development of antihuman IgG antibodies and hematologic Deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin. Comp. Med. 62: 31-36
15. Balakrishnan, K., L. C. Andrei-Selmer, T. Selmer, et al. 2010. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta. J. Alzheimers Dis. 20: 135-143
16. Klaver, A. C., J. M. Finke, J. Digambaranath, et al. 2010. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-Antigen-dissociated intravenous immunoglobulin preparations. Int. Immunopharmacol. 10: 115-119
17. Klaver, A. C., M. P. Coffey, L. M. Smith, D. A. Loeffler 2013. Comparison of ELISA measurements of anti-Ab concentrations and percentages of specific binding to Ab between unfractionated intravenous immunoglobulin products and their purified anti-Ab antibodies. Immunol. Lett. 154: 7-11
18. Wilks, S. S. 1962. Mathematical Statistics. John Wiley, New York.
19. Szabo, P., D. M. Mujalli, M. L. Rotondi, et al. 2010. Measurement of anti-beta amyloid antibodies in human blood. J. Neuroimmunol. 227: 167-174